Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Gross Profit (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Gross Profit for 4 consecutive years, with -$100088.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit fell 523.99% to -$100088.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $153842.0, a 95.54% increase, with the full-year FY2024 number at $222809.0, up 200.83% from a year prior.
  • Gross Profit was -$100088.0 for Q3 2025 at 60 Degrees Pharmaceuticals, down from $50881.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $112769.0 in Q4 2024 to a low of -$200009.0 in Q4 2022.
  • A 4-year average of -$7076.1 and a median of $23606.0 in 2024 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: skyrocketed 648.06% in 2024, then crashed 523.99% in 2025.
  • 60 Degrees Pharmaceuticals' Gross Profit stood at -$200009.0 in 2022, then skyrocketed by 89.71% to -$20576.0 in 2023, then surged by 648.06% to $112769.0 in 2024, then tumbled by 188.75% to -$100088.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Gross Profit are -$100088.0 (Q3 2025), $50881.0 (Q2 2025), and $90280.0 (Q1 2025).